Mesa Laboratories (NASDAQ:MLAB) Given New $106.00 Price Target at Evercore ISI

Mesa Laboratories (NASDAQ:MLAB) had its target price decreased by Evercore ISI from $120.00 to $106.00 in a research report released on Tuesday, Benzinga reports. Evercore ISI currently has an outperform rating on the medical instruments supplier’s stock.

Mesa Laboratories Price Performance

Shares of NASDAQ:MLAB opened at $87.73 on Tuesday. The business’s fifty day moving average price is $104.39 and its two-hundred day moving average price is $102.69. The stock has a market cap of $472.86 million, a PE ratio of -1.86 and a beta of 0.86. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.86 and a current ratio of 0.37. Mesa Laboratories has a one year low of $82.86 and a one year high of $145.46.

Mesa Laboratories (NASDAQ:MLAB) last announced its earnings results on Wednesday, June 5th. The medical instruments supplier reported $2.25 EPS for the quarter. Mesa Laboratories had a positive return on equity of 10.10% and a negative net margin of 117.61%. The firm had revenue of $58.90 million for the quarter. On average, analysts forecast that Mesa Laboratories will post 6.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Mesa Laboratories

Several hedge funds have recently made changes to their positions in the business. Motley Fool Asset Management LLC boosted its holdings in shares of Mesa Laboratories by 89.3% during the first quarter. Motley Fool Asset Management LLC now owns 16,488 shares of the medical instruments supplier’s stock worth $1,809,000 after purchasing an additional 7,779 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Mesa Laboratories by 6.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,873 shares of the medical instruments supplier’s stock valued at $316,000 after purchasing an additional 175 shares during the period. Keeley Teton Advisors LLC purchased a new position in Mesa Laboratories in the first quarter valued at about $2,606,000. EntryPoint Capital LLC increased its position in shares of Mesa Laboratories by 35.2% during the first quarter. EntryPoint Capital LLC now owns 741 shares of the medical instruments supplier’s stock worth $81,000 after acquiring an additional 193 shares during the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its position in shares of Mesa Laboratories by 7.6% during the first quarter. CANADA LIFE ASSURANCE Co now owns 6,968 shares of the medical instruments supplier’s stock worth $761,000 after acquiring an additional 494 shares during the last quarter. Institutional investors and hedge funds own 90.60% of the company’s stock.

About Mesa Laboratories

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.